ABS — Arctic Bioscience AS Share Price
Last trade - 00:00- NOK116.95m
- NOK85.97m
- NOK33.75m
- 33
- 35
- 21
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.99 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.5 | ||
| Price to Tang. Book | 1.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.19% | ||
| Return on Equity | -18.66% | ||
| Operating Margin | -159.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 30.04 | 20.5 | 21.52 | 34.27 | 33.75 | 43.5 | 78.5 | 2.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 7th, 2011
- Public Since
- February 24th, 2021
- No. of Employees
- 20
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 25,369,552
- Address
- Industrivegen 42, ORSTA, 6155
- Web
- https://arctic-bioscience.com/
- Phone
- Auditors
- Contabile AS
Upcoming Events for ABS
Similar to ABS
Navamedic ASA
Oslo Stock Exchange
Oncoinvent ASA
Oslo Stock Exchange
Photocure ASA
Oslo Stock Exchange
Vistin Pharma ASA
Oslo Stock Exchange
FAQ
As of Today at 19:19 UTC, shares in Arctic Bioscience AS are trading at NOK4.61. This share price information is delayed by 15 minutes.
Shares in Arctic Bioscience AS last closed at NOK4.61 and the price had moved by -54.31% over the past 365 days. In terms of relative price strength the Arctic Bioscience AS share price has underperformed the FTSE Global All Cap Index by -55.46% over the past year.
The overall consensus recommendation for Arctic Bioscience AS is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreArctic Bioscience AS does not currently pay a dividend.
Arctic Bioscience AS does not currently pay a dividend.
Arctic Bioscience AS does not currently pay a dividend.
To buy shares in Arctic Bioscience AS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK4.61, shares in Arctic Bioscience AS had a market capitalisation of NOK116.95m.
Here are the trading details for Arctic Bioscience AS:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: ABS
Based on an overall assessment of its quality, value and momentum Arctic Bioscience AS is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Arctic Bioscience AS is NOK2.50. That is 45.77% below the last closing price of NOK4.61.
Analysts covering Arctic Bioscience AS currently have a consensus Earnings Per Share (EPS) forecast of -NOK3.75 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arctic Bioscience AS. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +57.14%.
As of the last closing price of NOK4.61, shares in Arctic Bioscience AS were trading -27.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arctic Bioscience AS PE ratio based on its reported earnings over the past 12 months is 2.99. The shares last closed at NOK4.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arctic Bioscience AS' management team is headed by:
- Harald Nordal - CHM
- Hogne Hallaraker - CEO
- Per Saebo - COO
- Daniele Mancinelli - CTO
- Anders Blindheim - CMO